To date, five FDA-approved TNF-α inhibitors are being used in routine clinical practice to treat patients with rheumatoid and psoriatic arthritis, psoriasis, ankylosing spondylitis, or Crohn’s disease. This evidence concerns the gene TNF and psoriasis.